Q3 2025 IMCD NV Earnings Call Transcript
Key Points
- IMCD NV (IMCDY) achieved a 5% growth in gross profit on a constant currency basis, reaching EUR927 million, driven by organic performance and successful acquisitions.
- The company announced six acquisitions in 2025, expected to add around EUR340 million in revenue and 185 employees, strengthening its market position in Italy and South Korea.
- Pharmaceuticals, food, and nutrition segments showed solid performance, indicating resilience in these areas despite challenging market conditions.
- IMCD NV (IMCDY) is actively working on reducing inventory levels while maintaining sufficient stock to meet customer demands, showcasing effective inventory management.
- The company is intensifying efforts to drive cost effectiveness and commercial excellence, leveraging digital initiatives to optimize business operations and reduce FTEs.
- Challenging macroeconomic conditions, including tariff uncertainties, led to softer demand and limited order visibility across several markets.
- EBITA increased by only 1% on a constant currency basis, with a slight decrease in cash flow compared to the previous year due to lower EBITA and increased working capital investments.
- The company faces increased competition from Chinese suppliers, particularly impacting semi-specialty components in APAC and LatAm regions, leading to pricing pressure.
- Gross profit as a percentage of revenue slightly decreased to 25.2%, partly due to acquisitions with lower average gross profit margins.
- Currency fluctuations negatively impacted results in regions where transactions are commonly quoted in dollars but invoiced in local currencies, affecting LatAm, APAC, and some EMEA countries.
Hello. Welcome to the IMCD 2025 first nine months results conference call hosted by Marcus Jordan, CEO; and Hans Kooijmans. (Operator Instructions)
I would now like to give the floor to Marcus Jordan. Mr. Jordan, please go ahead.
Thank you very much, Elba. Good morning to you all, and a warm welcome. I'm Marcus Jordan, and I'm here today with our CFO, Hans Kooijmans for the 2025 first nine months results, which we published in a press release earlier this morning.
The first nine months of 2025 were generally characterized by challenging market conditions as a result of continued macroeconomic uncertainty, particularly around tariffs across all regions. This resulted in softer demand across a number of markets, limited order visibility, and just-in-time deliveries.
Moving on to the first nine months numbers. You will find a summary of our financial results on slide 4, whereby considering these continued challenging macroeconomic conditions, I am pleased
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

